SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla’s arm enters into agreement to sell 99% stake in AJDMA

09 Jun 2017 Evaluate

Cipla’s subsidiary - Saba Investment has entered into an agreement to sell its entire 99% equity stake in Al Jabal for Drugs and Medical Appliances Company, Yemen (AJDMA) to Khalil Ghaleb Ali Al-Jabal. The company has entered into an agreement for sale on June 7, 2017 and the transaction is expected to be closed within 35 days from Effective Date.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.


Cipla Share Price

1226.90 -6.00 (-0.49%)
22-Apr-2026 10:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1657.45
Dr. Reddys Lab 1213.00
Cipla 1226.90
Zydus Lifesciences 926.15
Lupin 2298.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×